ACAMBIS PLC
Similar Organizations
Artemis Medical
Artemis Medical is a Biotechnology company.
Icoria
Icoria is a Biotechnology company.
Pharmacia Biotech
Pharmacia Biotech is a Biotechnology company.
Vasogen Inc
Vasogen Inc is a Biotechnology company.
More informations about "Acambis plc"
Acambis plc - Cambridge, United Kingdom - bionity.com
Feb 27, 2008 Acambis plc was formerly known as Peptide Therapeutics Group PLC and changed its name to Acambis plc in December, 2000. The company was founded in 1992 and …See details»
Acambis Company Profile 2024: Valuation, Investors, Acquisition
Peptide Therapeutics Group Plc. Ownership Status. Acquired/Merged. Financing Status. Formerly PE-Backed. Corporate Office. ... Alta Berkeley, Prelude Ventures (Cambridge), and The …See details»
Acambis plc - Crunchbase Company Profile & Funding
Alternatives and possible competitors to Acambis plc may include Subintro, Vasogen Inc, and Artemis Medical. Unlock even more features with Crunchbase Pro Start Your Free TrialSee details»
Sanofi to buy vaccine maker Acambis for $548 mln | Reuters
Jul 28, 2008 Sanofi-Aventis SA <SASY.PA> agreed on Friday to buy British vaccine maker Acambis Plc <ACM.L> for 276 million pounds ($547.8 million), in a deal highlighting big drug …See details»
Sanofi-Aventis to complete Acambis deal - Financial Times
Sep 24, 2008 Sanofi-Aventis, the French pharmaceutical group, is set to complete its acquisition of Acambis of the UK on Thursday, with plans to keep the vaccine developer partly …See details»
Acambis PLC | www.inknowvation.com
Mar 8, 2019 Previously an independent, publicly held biopharmaceutical company, in May 1999 Acambis Inc, (formerly dba as Oravax) was acquired British firm Peptide Therapeutics Group …See details»
Sanofi Pasteur Completes the Acquisition of Acambis
Sep 25, 2008 Acambis' skilled workforce of individuals who share our passion for vaccines and prevention of infectious diseases will contribute to our efforts in answering unmet medical …See details»
Acambis Plc: Drug pipelines, Patents, Clinical trials - Synapse
Explore Acambis Plc with its drug pipeline, therapeutic area, technology platform, 2 clinical trials, 20 news, and 65 literature.See details»
Acambis plc - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Organization. Acambis plc . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. IT Spend by Aberdeen. Edit IT Spend by Aberdeen Section. This …See details»
PTL-16308 - Drug Targets, Indications, Patents - Synapse - Patsnap
PTL-16308: a Syk inhibitors, ZAP70 inhibitors Drug, Initially developed by Acambis Plc, Now, its global highest R&D status is Pending, Mechanism: Syk inhibitors ...See details»
Sanofi Pasteur completes Acambis vaccines takeover | Reuters
Sanofi Pasteur has completed the 285 million pound ($530 million) takeover of vaccines maker Acambis Plc, the vaccines division of French drugmaker Sanofi-Aventis <SASY.PA> said on …See details»
Acambis smallpox contract timeline slips back | Reuters
British vaccine maker Acambis Plc <ACM.L> said on Thursday it hoped to finalise an exclusive agreement with the U.S. government to supply smallpox vaccines by early next year. …See details»
Sanofi-Aventis to buy Acambis for about $549.5 mln
SAN FRANCISCO (MarketWatch) -- Sanofi Pasteur Holding, a vaccines division of Sanofi-Aventis , will buy United Kingdom's Acambis PLC for a total of about 276...See details»
Acambis shares soar on $548M buyout deal - Fierce Biotech
Jul 28, 2008 Shares of Acambis PLC soared after Sanofi-Aventis announced that it planned to buy the vaccine developer for $548 million. Aside from the smallpox vaccine ACAM2000, …See details»
PTL-11031 - Drug Targets, Indications, Patents - Synapse
PTL-11031: a Protease inhibitors, Viral protease modulators Drug, Initially developed by Acambis Plc, Now, its global highest R&D status is Pending, Mechanism: Protease inhibitors,Viral …See details»
Sanofi to acquire Acambis for $546M - Fierce Biotech
Jul 25, 2008 More evidence that the vaccine market is hot: vaccine maker Acambis has agreed to a £276 million ($546 million) by Sanofi-Pasteur, the vaccines division of France's Sanofi …See details»
TRANSFORMATION OF ACAMBIS - UCLA Fielding School of Public …
Apr 16, 2003 Transformation of Acambis. Smallpox pact frees firm from cash concerns. By Naomi Aoki, Globe Staff. CAMBRIDGE -- Acambis PLC is a rarity in the biotech industry: It …See details»
Sanofi makes $548M deal for Acambis - Fierce Pharma
Jul 28, 2008 Sanofi Pasteur has inked a deal to buy vaccine-maker Acambis for about $548 million (£276 million), a 64 percent per-share premium. The two companies had already been …See details»
Sanofi Pasteur and Acambis join forces to bring West Nile vaccine …
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has signed an exclusive global collaboration agreement with Acambis plc, for the development and …See details»